Dan Roden
Dan Roden
Professor of Medicine and Pharmacology, Vanderbilt University
Verified email at vanderbilt.edu - Homepage
Cited by
Cited by
Heart disease and stroke statistics—2015 update: a report from the American Heart Association
D Mozaffarian, EJ Benjamin, AS Go, DK Arnett, MJ Blaha, M Cushman, ...
circulation 131 (4), e29-e322, 2015
Heart disease and stroke statistics—2012 update: a report from the American Heart Association
Writing Group Members, VL Roger, AS Go, DM Lloyd-Jones, EJ Benjamin, ...
Circulation 125 (1), e2-e220, 2012
Goodman and Gilman's the pharmacological basis of therapeutics
AG Gilman
Harrison's principles of internal medicine
AS Fauci
McGraw-Hill Education, 2015
DP Zipes, AJ Camm, M Borggrefe, AE Buxton, B Chaitman, M Fromer, ...
Esc 8, 2006
Drug-induced prolongation of the QT interval
DM Roden
New England Journal of Medicine 350 (10), 1013-1022, 2004
Dual-chamber pacing or ventricular backup pacing in patients with an implantable defibrillator: the Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial.
BL Wilkoff, JR Cook, AE Epstein, HL Greene, AP Hallstrom, H Hsia, ...
Jama 288 (24), 3115-3123, 2002
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
RB Kim, MF Fromm, C Wandel, B Leake, AJ Wood, DM Roden, ...
The Journal of clinical investigation 101 (2), 289-294, 1998
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators
New England Journal of Medicine 337 (22), 1576-1584, 1997
Fulminant myocarditis with combination immune checkpoint blockade
DB Johnson, JM Balko, ML Compton, S Chalkias, J Gorham, Y Xu, ...
New England Journal of Medicine 375 (18), 1749-1755, 2016
Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
Cardiac Arrhythmia Suppression Trial II Investigators*
New England Journal of Medicine 327 (4), 227-233, 1992
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations
JC Denny, MD Ritchie, MA Basford, JM Pulley, L Bastarache, ...
Bioinformatics 26 (9), 1205-1210, 2010
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
SA Scott, K Sangkuhl, CM Stein, JS Hulot, JL Mega, DM Roden, TE Klein, ...
Clinical Pharmacology & Therapeutics 94 (3), 317-323, 2013
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation endorsed by …
BJ Drew, MJ Ackerman, M Funk, WB Gibler, P Kligfield, V Menon, ...
Journal of the American College of Cardiology 55 (9), 934-947, 2010
Taking the “idio” out of “idiosyncratic”: predicting torsades de pointes
DM Roden
Pacing and Clinical Electrophysiology 21 (5), 1029-1034, 1998
Long-QT syndrome
DM Roden
New England Journal of Medicine 358 (2), 169-176, 2008
Development of a large‐scale de‐identified DNA biobank to enable personalized medicine
DM Roden, JM Pulley, MA Basford, GR Bernard, EW Clayton, JR Balser, ...
Clinical Pharmacology & Therapeutics 84 (3), 362-369, 2008
Genetic determinants of response to warfarin during initial anticoagulation
UI Schwarz, MD Ritchie, Y Bradford, C Li, SM Dudek, A Frye-Anderson, ...
New England Journal of Medicine 358 (10), 999-1008, 2008
Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions
DM Roden, R Lazzara, M Rosen, PJ Schwartz, J Towbin, GM Vincent
Circulation 94 (8), 1996-2012, 1996
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data
JC Denny, L Bastarache, MD Ritchie, RJ Carroll, R Zink, JD Mosley, ...
Nature biotechnology 31 (12), 1102-1111, 2013
The system can't perform the operation now. Try again later.
Articles 1–20